Article citationsMore>>

Eliakim-Raz, N., Babitch, T., Shaw, E., Addy, I., Wiegand, I., Vank, C., Torre-Vallejo, L., Joan-Miquel, V., Steve, M., Grier, S., Stoddart, M., Nienke, C., Leo, V.D.H., Vuong, C., MacGowan, A., Carratalà, J., Leibovici, L., Pujol, M. and RESCUING Study Group. (2019) Risk Factors for Treatment Failure and Mortality among Hospitalized Patients with Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group). Clinical Infectious Diseases, 68, 29-36.
https://doi.org/10.1093/cid/ciy418

has been cited by the following article:

• TITLE: Appropriateness of Amikacin Dose Prescription, Monitoring and Safety during Hospitalization as an Impact of Clinical Pharmacologist Intervention, in the Israeli Regional Hospital

  AUTHORS: Renata Shihmanter, Olga Lazar, Lidia Arcavi

  KEYWORDS: Amikacin, Therapeutic Drug Monitoring, Appropriate, Clinical Pharmacologist, Safety, Adverse Effects

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.3, March 29, 2024

  ABSTRACT: Background: Use of inappropriate amikacin dose is one of the most important factors in inducing toxicity, prolonged hospitalization as well as in increasing patient’s mortality. Objective: The aims of this study are the analysis of amikacin dose, serum level and the examination of the effectiveness of the clinical pharmacologist (CP) therapeutic drug monitoring (TDM) intervention to guarantee the safety of amikacin use. Methods: This is a one-year retrospective observational chart review study, which evaluates amikacin dose, serum drug level, development of adverse effects in patients on amikacin with or without CP TDM consultation. Results: Amikacin was prescribed for 393 complex patients, with median age 83. Amikacin group (AG) included 140 (32%) courses with CP consultation (AG1) and 292 (68%) courses without CP consultation (AG2). The distribution of most study characteristics in both groups was similar including amikacin dose (9-10 mg/kg/day), renal failure (14%) and mortality (12%). Acceptance for CP consultation was in 46% of amikacin courses and dose changes were done in 63% after CP intervention. Prolonged antibiotic course (4.6 ± 1.5 vs 3.8 ± 1.6 days, p Conclusions: There was no trend to reducing amikacin toxicity, days of hospitaliza tion or mortality in patients with CP consultation. CP TDM intervention was more in the management of complicated clinical situations. However, it is necessary to optimize it.